The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Tabitha Reed and Julia Cockroft examine the Tribunal’s ruling, its implications for suppliers of branded medicines, and ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Boehringer Ingelheim will conduct biophysical and structural studies ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

Boehringer Ingelheim is a biopharmaceutical company active in both ... Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...